News
3d
US Weekly on MSNWhat to Know About ‘The Handmaid’s Tale’ Spinoff ‘The Testaments’: Returning Cast Members and MoreHulu's spinoff of 'The Handmaid's Tale' titled 'The Testaments' comes after the original show's sixth and final season ...
5d
Screen Rant on MSNHow The Handmaid's Tale Sequel Show Approaches Gilead Differently Explained By EPsExclusive: Bruce Miller and Warren Littlefield explain how The Handmaid's Tale's sequel show, The Testaments, approaches ...
The Handmaid’s Tale Season 6 finale is just a few weeks away, but fans hoping for a neatly wrapped story to June Osbourne and ...
1d
Zacks Investment Research on MSNWhat Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 EarningsWall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.73 per share in its upcoming report, which indicates a year-over-year increase of 231.1%. Revenues are expected to ...
As the final season of "The Handmaid's Tale" begins today, we're taking a look back on everything to know about the hit Hulu ...
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
"It's not about a relationship she chose, like with Fred," Bruce Miller says, explaining why writers chose to introduce the ...
Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...
Four episodes into the final season of The Handmaid's Tale, June's (Elisabeth Moss) quest to destroy Gilead is back in full ...
Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...
Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results